> ## Content Index
> Fetch the complete content index at: https://www.moatmarginresearch.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Eris Lifesciences Moat Analysis: Score & Risks
- URL: https://www.moatmarginresearch.com/eris-lifesciences-moat/
- Published: 2026-08-16T16:20:51.000Z
- Updated: 2026-08-22T05:14:14.000Z
- Author: A K Karthikeyan
- Tags: First-pass note, Coverage

Moat Note · First-pass

## Eris Lifesciences Ltd.

A first-pass moat teardown of Eris Lifesciences Ltd., built from single-pass filing evidence. Free note — provisional, and the full two-pass deep dive may revise it.

**Moat & Margin**16 Aug 2026 First-pass · \~3 min

5.31 / 10

NARROWProcess/Data-led

First-pass narrow read — primary edge in Cost Advantage. Provisional, single-pass evidence.

Provisional score · subject to modification based on new evidence

Eris Lifesciences Ltd. scores **5.31** on MoatSCORE 6.0 — a narrow moat in Pharma. This is a **first-pass note**: the dimensional read and the filing receipts below come from a single GFIP evidence pass, not the full two-pass deep corpus behind our flagship deep dives. Provisional — published free while the deep version is queued.

The teardown 

## Seven dimensions of moat

Ordered by contribution. Each dimension carries a verified filing quote, graded **\[M\]** mechanism or **\[O\]** outcome.

D3Cost Advantage6

M · Mechanism✓ Verified verbatim

“Operating leverage: The manufacturing facility in Guwahati, Assam currently operating at ≈80% capacity utilisation on a two shift basis is capable of being scaled up to triple shift basis.”

**Eris Lifesciences Ltd.** · Annual Report · p.61

D4Price Discretion6

M · Mechanism✓ Verified verbatim

“Domestic Branded Formulations EBITDA margin expanded from 34.5% in FY24 to 36.5% in FY25; an increase of \~200 bps driven by synergies from business integration.”

**Eris Lifesciences Ltd.** · FY2024-25 Annual Report · p.89

D5Intangible Assets6

M · Mechanism✓ Verified verbatim

“further solidified our position with marquee brands such as Basalog and Insugen into our th portfolio making Eris the 5 largest Diabetes franchise in India.”

**Eris Lifesciences Ltd.** · FY2024-25 Annual Report · p.35

D6Efficient Scale6

M · Mechanism✓ Verified verbatim

“Swiss Parenterals now ranks among a select few Indian injectable cos to have received both EU and ANVISA regulatory approvals”

**Eris Lifesciences Ltd.** · Investor Presentation · p.33

D1Network Effects5.7

M · Mechanism✓ Verified verbatim

“Kunal, our DBF MR strength is close to 3,700-plus now. More than 560 reps added through the two Biocon deals. That's where we stand right now.”

**Eris Lifesciences Ltd.** · Earnings Call · p.12

D2Switching Costs5.2

M · Mechanism✓ Verified verbatim

“the business model would be to look at 3-to-5-year manufacturing contracts for sale in the EU, and these come with higher customer stickiness and lower price sensitivity given that these are injectables.”

**Eris Lifesciences Ltd.** · Earnings Call · p.6

D7Counter-PositioningExcluded—

Excluded for this archetype.

D8Ungoverned RiskUnscored · Layer 2.5

D8 rating: **ADEQUATE**. Not part of the moat score — it governs the cost of equity and the fade window. First-pass; not yet deep-reviewed.

The barrier gate 

## The barrier gate — first-pass

Replication — can a rival copy it?6.0

How hard it is for a rival to copy the edge (first-pass estimate).

Bypass — can a rival route around it?6.0

How easily a rival can route around the edge (first-pass estimate).

Effective barrier 6 — at or above 6, consistent with a narrow read. First-pass estimate.

What would change our mind

1. **Deep two-pass review.** This draft rests on a single GFIP evidence pass; the full 10-year AR + concall corpus may move the read.
2. **The barrier gate.** A firmer replication or bypass estimate is the most likely thing to shift the band.
3. **Adverse events.** Any governance, regulatory or funding shock captured in D8 could re-rate the fade window.

First-pass note — provisional single-pass MoatSCORE 6.0 read, not the full deep dive. Educational research, not investment advice; no buy/sell recommendation, no price target. Moat & Margin is not a SEBI-registered Research Analyst or Investment Adviser.

**Where this note fits.** This company is one of **509 Indian companies** we have scored for moat durability — 370 narrow, 126 narrow-trending-wide, none wide. Every score, dimension by dimension, is free in the [Moat Screener](https://www.moatmarginresearch.com/moat-screener/).